Search

Search Constraints

You searched for: Author/Creator Thepot, Sylvain

Search Results

1. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. (19th April 2022)

2. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Issue 10 (14th July 2015)

3. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. Issue 10 (1st April 2023)

4. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Issue 1 (1st January 2021)

5. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide. (21st September 2021)

6. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Issue 12 (2nd December 2018)

7. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). Issue 5 (22nd April 2022)

8. R‐DHA‐oxaliplatin (R‐DHAOx) versus R‐DHA‐cisplatin (R‐DHAP) regimen in B‐cell lymphoma treatment: A eight‐year trajectory study. (11th May 2020)